Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Celldex Therapeutics
(NQ:
CLDX
)
41.16
-0.69 (-1.65%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Celldex Therapeutics
< Previous
1
2
3
4
5
Next >
Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
February 26, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
February 24, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
February 06, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Forecasting The Future: 5 Analyst Projections For Celldex Therapeutics
December 20, 2023
Via
Benzinga
What 7 Analyst Ratings Have To Say About Celldex Therapeutics
November 10, 2023
Via
Benzinga
Celldex Therapeutics Inc. (NASDAQ: CLDX) Highlighted for Surprising Price Action
November 06, 2023
Via
Investor Brand Network
Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024
February 05, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Top Picks 2024: Celldex Therapeutics, Inc.
January 28, 2024
Celldex Therapeutics is one of our top picks for the year. With very good data and the financing behind it, now could be the time to take advantage of the pullback in shares to initiate and/or add to...
Via
Talk Markets
Top 4 Health Care Stocks That May Crash This Month
December 20, 2023
As of Dec. 20, 2023, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Via
Benzinga
Celldex Therapeutics to Present at 6th Annual Evercore ISI HealthCONx Conference
November 27, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Biotech Breakthroughs: 3 Revolutionary Stocks Redefining Healthcare
November 17, 2023
Are you looking for biotech breakthrough stocks? Here are three revolutionary stocks redefining healthcare.
Via
InvestorPlace
Why Celldex Therapeutics (CLDX) Stock Is Getting Hammered
November 08, 2023
Celldex Therapeutics, Inc. (NASDAQ: CLDX) shares are trading lower after the company announced a proposed public offering of 7.425 million shares at $27 per share.
Via
Benzinga
Celldex Therapeutics Announces Pricing of Public Offering of Common Stock
November 07, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
November 07, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Why Celldex Therapeutics Blasted 13% Higher on Monday
November 06, 2023
The biotech's CSU treatment advanced in the laboratory.
Via
The Motley Fool
Celldex Makes A Bullish Move As It Looks To Take On Regeneron, Sanofi
November 06, 2023
The company is looking to take on Regeneron and Sanofi's Dupixent in skin diseases.
Via
Investor's Business Daily
Why Bluegreen Vacations Shares Are Trading Higher By Around 105%? Here Are Other Stocks Moving In Monday's Mid-Day Session
November 06, 2023
Gainers Carbon Revolution Public Limited (NASDAQ: CREV) shares jumped 396.2% to $145.49 after gaining 100% on Friday. The company’s stock began trading on Friday following merger with Twin Ridge...
Via
Benzinga
Why Is Inflammation Disease-Focused Celldex Therapeutics Stock Trading Higher Today?
November 06, 2023
Celldex Therapeutics Inc (NASDAQ: CLDX) released topline results from its Phase 2 trial of barzolvolimab in patients with moderate to severe chronic spontaneous urticaria (CSU) refractory to...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
November 06, 2023
Via
Benzinga
Celldex Therapeutics Announces Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
November 06, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Therapeutics Presents Positive Data from Prurigo Nodularis Phase 1b Study Demonstrating Meaningful Reduction in Itch and Skin Clearing with Single Dose 3.0 mg/kg Barzolvolimab
November 05, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 02, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results in Prurigo Nodularis at 12th World Congress on Itch (WCI) 2023
September 26, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Therapeutics to Present at Cantor Global Healthcare Conference
September 25, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Wall Street's Top 10 Stock Calls This Week - Sunday, Aug. 27
August 27, 2023
Via
Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For August 22, 2023
August 22, 2023
Via
Benzinga
Celldex Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 08, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria
July 11, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis
July 06, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Therapeutics Presents Positive Data from Barzolvolimab Chronic Urticaria Program at EAACI 2023
June 10, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.